- Ocugen press release ( NASDAQ: OCGN ): Q3 GAAP EPS of -$0.10 in-line.
- The Company’s cash, cash equivalents, and restricted cash totaled $101.6 million as of September 30, 2022, compared to $95.1 million as of December 31, 2021
-
- Initiated dosing in the third and final cohort of U.S. Phase 1/2 OCU400 gene therapy clinical trial
- Expanded product pipeline with OCU500—Ocugen’s mucosal COVID-19 vaccine and OCU410ST for Stargardt disease
- Completed enrollment of U.S. Phase 2/3 COVAXIN™ (BBV152) clinical trial
- Shares +1.96% PM.
For further details see:
Ocugen GAAP EPS of -$0.10 in-line